Pro Share Advisors LLC Iveric Bio, Inc. Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$26.24 - $39.63 $275,021 - $415,362	10,481 Added 41.09%	35,988 $1.42 Million
Q1 2023 May 11, 2023	SELL	$18.67 - $24.56 $33,456 - $44,011	-1,792 Reduced 6.56%	25,507 $620,000
Q4 2022 Feb 02, 2023	BUY	$17.24 - $23.95 $74,149 - $103,008	4,301 Added 18.7%	27,299 $584,000
Q3 2022 Nov 04, 2022	BUY	$9.4 - $18.59 $7,576 - $14,983	806 Added 3.63%	22,998 $412,000
Q2 2022 Aug 01, 2022	SELL	$9.12 - $18.9 $103,548 - $214,590	-11,354 Reduced 33.85%	22,192 $213,000

Q1 2022 May 10, 2022	SELL	$12.15 - $16.83 $93,506 - $129,523	-7,696 Reduced 18.66%	33,546 $565,000
Q4 2021 Feb 08, 2022	BUY	$13.83 - $18.78 $78,056 - $105,994	5,644 Added 15.85%	41,242 $689,000
Q3 2021 Nov 12, 2021	SELL	$7.07 - $17.5 $29,100 - $72,030	-4,116 Reduced 10.36%	35,598 $578,000
Q2 2021 Aug 13, 2021	BUY	$5.69 - $7.17 $33,303 - $41,966	5,853 Added 17.29%	39,714 $251,000
Q1 2021 May 14, 2021	BUY	$5.08 - $6.89 $11,404 - $15,468	2,245 Added 7.1%	33,861 $209,000
Q4 2020 Feb 09, 2021	BUY	$5.65 - $7.66 $178,630 - $242,178	31,616 New	31,616 $218,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.